Episurf Medical enters into its first strategic partnership regarding its AI-based imaging technology
Episurf Medical (NASDAQ: EPIS B) today announces that it has entered into a Letter of Intent with a US-based orthopaedic company related to Episurf Medical’s proprietary and patented imaging technology, now to be applied for the allograft industry. While the details and financial considerations of the Letter of Intent are currently confidential, both parties have the intention to collaborate using Episurf Medical’s Epioscopy® technology platform for surgery planning within allograft joint surgery. In September 2018, Episurf Medical announced that the company had CE-marked its